Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023
MMWR. Morbidity and Mortality Weekly Report · 21.07.2023 · 72 (29) · 793-801
DOI: 10.15585/mmwr.mm7229a4 ↗Kurz gefasst
Fachartikel in der Zeitschrift MMWR. Morbidity and Mortality Weekly Report, online erschienen am 21.07.2023. Verfasst von Michael Melgar und 6 weiteren Autor:innen. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Vaccines, Respiratory Syncytial Virus, Human, Respiratory Syncytial Virus Infections, Respiratory Tract Diseases. Die Arbeit wurde bisher 326-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Gerontologische Pflege
Abstract (Originalsprache)
Respiratory syncytial virus (RSV) is a cause of severe respiratory illness in older adults. In May 2023, the Food and Drug Administration approved the first vaccines for prevention of RSV-associated lower respiratory tract disease in adults aged ≥60 years. Since May 2022, the Advisory Committee on Immunization Practices (ACIP) Respiratory Syncytial Virus Vaccines Adult Work Group met at least monthly to review available evidence regarding the safety, immunogenicity, and efficacy of these vaccines among adults aged ≥60 years. On June 21, 2023, ACIP voted to recommend that adults aged ≥60 years may receive a single dose of an RSV vaccine, using shared clinical decision-making. This report summarizes the body of evidence considered for this recommendation and provides clinical guidance for the use of RSV vaccines in adults aged ≥60 years. RSV vaccines have demonstrated moderate to high efficacy in preventing RSV-associated lower respiratory tract disease and have the potential to prevent substantial morbidity and mortality among older adults; postmarketing surveillance will direct future guidance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Melgar, M., Britton, A., Roper, L. E., Talbot, H. K., Long, S. S., Kotton, C. N., & Havers, F. P. (2023). Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023. MMWR. Morbidity and Mortality Weekly Report, 72(29), 793-801. https://doi.org/10.15585/mmwr.mm7229a4
Vancouver
Melgar M, Britton A, Roper LE, Talbot HK, Long SS, Kotton CN, et al. Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023. MMWR. Morbidity and Mortality Weekly Report. 2023;72(29):793-801. doi:10.15585/mmwr.mm7229a4
BibTeX
@article{Melgar2023,
author = {Melgar, Michael and Britton, Amadea and Roper, Lauren E and Talbot, H Keipp and Long, Sarah S and Kotton, Camille N and Havers, Fiona P},
title = {Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023},
journal = {MMWR. Morbidity and Mortality Weekly Report},
year = {2023},
volume = {72},
number = {29},
pages = {793--801},
doi = {10.15585/mmwr.mm7229a4}
}
EUVIMED